Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Background: Blood pressure reduction achieved with beta-blockers and diuretics is the best recorded intervention to date for prevention of cardiovascular morbidity and death in patients with hypertension. Left ventricular hypertrophy (LVH) is a strong independent indicator of risk of cardiovascular...

Descripción completa

Detalles Bibliográficos

Publicado en:	Lancet Vol. 359; no. 9311; pp. 995 - 1004
Autores principales:	Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, Dahlöf, Björn, Devereux, Richard B, Kjeldsen, Sverre E, Julius, Stevo, Beevers, Gareth
Formato:	clinical trial research tables/charts Journal Article
Publicado:	Lancet 3/23/2002
Acceso en línea:	Ver este registro en EBSCOhost